Literature DB >> 25298596

Stevens Johnson syndrome and neurotoxic effects of metronidazole.

Rahul Magazine1, Bharti Chogtu2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25298596      PMCID: PMC4175903          DOI: 10.4103/0253-7613.140602

Source DB:  PubMed          Journal:  Indian J Pharmacol        ISSN: 0253-7613            Impact factor:   1.200


× No keyword cloud information.
Sir, Stevens Johnson syndrome (SJS) is a severe cutaneous adverse drug reaction and predominantly involves the skin and mucous membranes. In most cases developing SJS, the risks remain unidentifiable.[1] Drugs that commonly cause SJS are sulphonamides, nevirapine, allopurinol, lamotrigine, aromatic anticonvulsants, and oxicam nonsteroidal anti-inflammatory drugs (NSAIDs). Drugs with long half-lives are more likely to cause such fatal reactions than those with short half-lives.[2] In Drug watch published in Jan–Feb 2014 issue of the Indian Journal of Pharmacology, the authors have reported a case of metronidazole-induced SJS in a patient in whom symptoms started 6 hours after first dose and progressed after second dose.[3] As mentioned by authors, there is one case reported by Piskin and Makkes in which patient started developing symptoms 1 day after initiating of metronidazole. Authors have also reported that the cutaneous drug reaction was accompanied by early central nervous system (CNS) symptoms like dizziness, confusion, convulsions, and loss of consciousness for 15-20 min. They consider the CNS manifestations to be a part of SJS. However, in our view, the CNS symptoms experienced in this case can be explained separately as metronidazole-induced adverse effect. Though, metronidazole-induced encephalopathy is relatively rare,[4] it needs to be considered because of its use in both medical and surgical patients. CNS toxicity with metronidazole does not seem to be a dose- or duration-related phenomenon.[5] Magnetic resonance imaging (MRI) abnormalities are seen in most patients. Theories suggested for CNS changes include axonal swelling with increased water content due to toxic injury or localized reversible ischemia due to vascular spasm.[6] It can also be due to interstitial edema or purkinje cell damage due to binding of the metronidazole to neuronal ribonucleic acid (RNA), causing inhibition of protein synthesis and resulting in axonal degeneration.[6] The prognosis of metronidazole-induced CNS adverse effects is excellent, once metronidazole is stopped.
  6 in total

Review 1.  Metronidazole-induced Encephalopathy: Case Report and Review Literature.

Authors:  Ying-Ting Huang; Lu-An Chen; Shin-Jung Cheng
Journal:  Acta Neurol Taiwan       Date:  2012-06

2.  Stevens-Johnson syndrome in India - risk factors, ocular manifestations and management.

Authors:  N Pushker; R Tandon; R B Vajpayee
Journal:  Ophthalmologica       Date:  2000       Impact factor: 3.250

3.  Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy.

Authors:  A Ahmed; D J Loes; E L Bressler
Journal:  Neurology       Date:  1995-03       Impact factor: 9.910

4.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?

Authors:  I Garcia-Doval; L LeCleach; H Bocquet; X L Otero; J C Roujeau
Journal:  Arch Dermatol       Date:  2000-03

Review 5.  Metronidazole-induced central nervous system toxicity: a systematic review.

Authors:  Akira Kuriyama; Jeffrey L Jackson; Asako Doi; Toru Kamiya
Journal:  Clin Neuropharmacol       Date:  2011 Nov-Dec       Impact factor: 1.592

6.  Stevens-Johnson syndrome following use of metronidazole in a dental patient.

Authors:  Goutameswar Mazumdar; Koushik Shome
Journal:  Indian J Pharmacol       Date:  2014 Jan-Feb       Impact factor: 1.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.